RAPID MICRO BIOSYSTEMS, INC. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 95/100
What the filing says
Rapid Micro Biosystems signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany via tender offer (share count and price undisclosed in this filing). Q3 2026 revenue grew 22% to $9.5M with gross margin expanding to 25% (from 9% YoY), but the company remains unprofitable: net loss $11.3M, with ~$7M cash on hand and $19.2M notes payable outstanding. CEO stated 18-month prior partnership with Merck underpins deal rationale.
Why this rating
Acquisition terminates public company status and eliminates standalone going-concern risk. For $103.6M market-cap biotech, deal certainty and Merck backing are transformational. No price disclosed; risk remains.
Tradability signal
NO TRADE
No trade: positive news with only -0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +2.01% over 4 hrs, n=49).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.74 ▲ 0.00% | at our read · unknown $0.73 | +10 min · unknown $0.73 ▼ 0.14% | +30 min · unknown $0.73 ▲ 0.00% | +1 hr · unknown $0.73 ▲ 0.00% | +4 hrs · unknown $0.73 ▲ 0.00% |
The stock had already moved -0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.